Peripheral Artery Disease (PAD) Treatment: Evidence-Based Clinical Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Peripheral Artery Disease (PAD) is a manifestation of systemic atherosclerosis causing narrowing and occlusion of the arteries supplying the lower limbs (and less commonly the upper limbs). It affects approximately 200 million people worldwide and is a major cause of morbidity, limb loss, and cardiovascular mortality. PAD shares the same pathophysiological basis as coronary artery disease and cerebrovascular disease — lipid accumulation, endothelial dysfunction, plaque formation, and thrombosis — and patients with PAD have a 2-6 times higher risk of myocardial infarction and stroke compared to age-matched controls, with a 15-30% 5-year cardiovascular mortality.

The diagnosis of PAD is established by the Ankle-Brachial Index (ABI): the ratio of systolic blood pressure at the ankle (measured by Doppler ultrasound over the posterior tibial or dorsalis pedis artery) to the brachial systolic pressure. A resting ABI of:

• 1.0-1.4: Normal.
• 0.9-1.0: Borderline; may warrant exercise ABI testing.
• <0.9: Diagnostic of PAD (sensitivity 79%, specificity 96% for ≥50% stenosis on angiography).
• 0.4-0.9: Symptomatic PAD, typically presenting as intermittent claudication.
• <0.4: Critical limb ischaemia (CLI) / chronic limb-threatening ischaemia (CLTI) — rest pain, tissue loss, or gangrene; requires urgent revascularisation assessment.
• >1.4: Non-compressible arteries (calcified, often in diabetics) — ABI unreliable; toe-brachial index (TBI), transcutaneous oxygen pressure (TcPO2), or CT angiography needed.

PAD is staged clinically using two complementary classification systems: the Fontaine Classification (I-IV) used primarily in Europe, and the Rutherford Classification (Categories 0-6) used primarily in North America. Treatment intensity is determined by the Fontaine/Rutherford stage, ABI value, imaging findings, and patient-specific cardiovascular risk profile.

Treatment encompasses three dimensions: cardiovascular risk factor modification (to reduce systemic MACE risk), symptom management (for claudication), and limb revascularisation (for CLTI to prevent amputation). The optimal strategy integrates all three simultaneously under a vascular multidisciplinary team.

PAD is classified by clinical severity to guide appropriate management intensity and urgency. The Fontaine Classification and Rutherford Classification are the two principal frameworks in clinical use.

Fontaine Classification:

• Stage I — Asymptomatic PAD: ABI <0.9 confirmed by Doppler but no symptoms. Relatively common — up to 50% of patients with haemodynamically significant PAD are asymptomatic. Requires cardiovascular risk factor optimisation and monitoring; no limb-directed intervention indicated.
• Stage IIa — Mild Claudication: Intermittent claudication with a walking distance >200 metres before onset of pain. Calf, thigh, or buttock muscle cramping that resolves within 10 minutes of rest. Managed with supervised exercise therapy (SET) and medical optimisation.
• Stage IIb — Moderate-to-Severe Claudication: Walking distance <200 metres. Significantly impaired quality of life. SET first-line; endovascular intervention (angioplasty/stenting) considered for lifestyle-limiting symptoms after failed SET or for anatomically favourable lesions (aorto-iliac disease).
• Stage III — Ischaemic Rest Pain: Constant aching or burning pain in the foot at rest (typically worse when lying flat — relieved by dependency). ABI typically <0.4. Indicates critical limb ischaemia (CLI); urgent revascularisation planning required.
• Stage IV — Ulceration or Gangrene: Tissue loss — ischaemic ulceration or gangrene. The most severe manifestation of PAD. Requires urgent intervention to achieve limb salvage; major amputation risk is high without revascularisation.

Rutherford Classification subdivides these categories into 7 grades (0-6) for more precise clinical trial stratification. Category 4 (rest pain), 5 (minor tissue loss), and 6 (major tissue loss) constitute CLTI (Chronic Limb-Threatening Ischaemia) — the contemporary term replacing CLI, reflecting the chronicity of the condition.

The WIFI classification (Wound, Ischaemia, foot Infection) further characterises CLTI by integrating wound grade, ABI/TBI, and infection severity to predict amputation risk and stratify intervention benefit — adopted in the 2019 Global Vascular Guidelines for CLTI.

All patients with confirmed PAD (ABI <0.9 or equivalent Doppler criteria) require cardiovascular risk factor modification regardless of symptom severity. Eligibility for invasive procedures (endovascular or surgical) depends on symptom burden, anatomical disease pattern, and the patient’s overall fitness and life expectancy.

Assessment for supervised exercise therapy (SET):

• All patients with intermittent claudication (Fontaine IIa/IIb, Rutherford 1-3) who are not yet ambulatory-limited should be offered SET before any invasive procedure.
• Exercise ABI testing (post-treadmill ABI measurement) confirms haemodynamic significance of suspected PAD and provides baseline walking distance for programme monitoring.
• Cardiac evaluation may be required before SET in patients with reduced exercise tolerance that may reflect unrecognised coronary artery disease. Dobutamine stress echocardiography or nuclear perfusion imaging may be indicated.

Assessment for endovascular or surgical intervention:

• Duplex ultrasound mapping of the peripheral arterial tree is the first imaging modality — non-invasive, no radiation, identifies occlusions and stenoses from aorta to pedal arteries.
• CT angiography (CTA) or MR angiography (MRA) provides anatomical roadmap for complex multilevel disease and surgical planning. CTA requires iodinated contrast; MRA avoids radiation but is slower and less widely available.
• Catheter-based digital subtraction angiography (DSA) is reserved for cases where treatment is anticipated at the same session (endovascular intervention) or when non-invasive imaging is equivocal.
• For CLTI: physiological assessment using transcutaneous oxygen pressure (TcPO2) — values <30 mmHg at the dorsum of the foot indicate severe ischaemia with poor healing potential; <20 mmHg predicts high amputation risk without revascularisation. Toe pressure >50 mmHg generally supports wound healing capacity.
• Overall surgical fitness assessed by cardiology (stress testing, echocardiography), with optimisation of cardiac, renal, and respiratory comorbidities before elective intervention.

Patients with severe comorbidities (recent MI, severe COPD, advanced renal failure, dementia) may not be candidates for invasive revascularisation; primary amputation or palliative pain management may be more appropriate in these cases.

PAD treatment is stratified by disease stage and is best delivered by a vascular multidisciplinary team (vMDT) comprising vascular surgeons, interventional radiologists, vascular physicians, diabetes specialists, wound care nurses, and physiotherapists.

1. Cardiovascular Risk Factor Modification (ALL patients, ALL stages):

• Statins (mandatory): High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) reduces major adverse cardiovascular events (MACE — MI, stroke, cardiovascular death) by 25-35% in PAD patients, regardless of baseline LDL-cholesterol. Target LDL <1.8 mmol/L (<70 mg/dL); <1.4 mmol/L for very high-risk CLTI patients per ESC 2019 Dyslipidaemia Guidelines.
• Antiplatelet therapy (mandatory): Single antiplatelet therapy — clopidogrel 75 mg once daily (preferred in PAD based on CAPRIE trial — 23.8% relative risk reduction in MACE vs aspirin) or aspirin 75-100 mg once daily. Dual antiplatelet therapy (aspirin + clopidogrel) is not routinely recommended for stable claudication (excess bleeding risk) but is indicated post-endovascular stenting per device guidelines.
• ACEI/ARB: Ramipril demonstrated significant MACE reduction in PAD patients in the HOPE trial (even in normotensive patients); recommended for all PAD patients tolerating ACE inhibitors.
• Blood pressure control: Target <140/90 mmHg; <130/80 mmHg in diabetics. Beta-blockers were historically avoided in PAD (theoretical concern of worsening claudication) but are NOT contraindicated — they improve cardiovascular outcomes and mild claudication worsening is acceptable for appropriate cardiac indications.
• Diabetes management: HbA1c target <7.0% (53 mmol/mol) to reduce microvascular complications; SGLT-2 inhibitors (empagliflozin, canagliflozin) have demonstrated additional cardiovascular and renal benefit in diabetic PAD patients.
• Smoking cessation: Smoking is the most important modifiable risk factor for PAD progression. Continued smoking reduces patency rates of all revascularisation procedures; doubles the amputation rate. Varenicline, nicotine replacement, and bupropion are first-line cessation aids.

2. Supervised Exercise Therapy (SET) for Claudication:

• SET involves structured treadmill or track walking sessions 3 times per week for a minimum of 12 weeks, under physiotherapy supervision, with progressive pain-free walking intervals.
• The CLEVER trial (Claudication: Exercise Versus Endoluminal Revascularization) compared SET, optimal medical care (OMC), and iliac stenting for aorto-iliac PAD. At 18 months, SET was superior to stenting in peak walking time improvement (5.8 min improvement vs 3.7 min with stenting). Both were superior to OMC alone. At 3-year follow-up, the stent group recovered to equivalent outcomes. SET is therefore first-line for Fontaine IIa-IIb before invasive intervention.
• Cilostazol (Pletal) 100 mg twice daily: The only FDA-approved pharmacotherapy for intermittent claudication. A selective phosphodiesterase-3 (PDE-3) inhibitor with vasodilatory and antiplatelet properties. Meta-analyses show cilostazol improves pain-free walking distance by 40-60% and maximum walking distance by 25-50% compared to placebo. Contraindicated in heart failure (any grade) due to PDE-3 inhibition in myocardium. Common side effects: headache, palpitations, diarrhoea. Pentoxifylline (alternative agent) shows weaker evidence and is less preferred.

3. Endovascular Revascularisation:

• Angioplasty (PTA) and stenting: Percutaneous transluminal angioplasty with or without stent placement. Technique, stent type, and approach vary by lesion site and morphology per TASC II classification:
  • Aorto-iliac segment: Excellent long-term patency (80-85% at 5 years for stenting). Iliac stenting is first-line for TASC A-B lesions; surgery preferred for TASC C-D complex disease.
  • Superficial femoral artery (SFA): Nitinol self-expanding stents (e.g., Innova, LifeStent) provide 5-year patency of 60-70% for femoropopliteal lesions. Drug-coated balloons (DCB — paclitaxel or sirolimus) and drug-eluting stents reduce restenosis rates. An updated meta-analysis mortality signal with paclitaxel DCBs (Katsanos et al.) prompted FDA review; subsequent large RCTs (SWEDEPAD) did not confirm excess mortality, and paclitaxel DCBs remain in guideline-recommended use with appropriate patient counselling.
  • Below-knee (infrapopliteal) lesions: For CLTI with isolated tibial disease — balloon angioplasty; drug-coated balloons show variable benefit. Endovascular is preferred given high surgical risk of infrapopliteal bypass in this patient population.
• BASIL-2 trial (Bypass versus Angioplasty in Severe Ischaemia of the Leg-2): 345 patients with CLTI requiring above-knee revascularisation randomised to best endovascular treatment (BET) first or vein bypass first. BET-first was non-inferior and associated with reduced procedural morbidity. Results support endovascular-first approach for above-knee CLTI when anatomically feasible.

4. Surgical Bypass: For CLTI with complex multilevel disease, failed endovascular, or TASC D lesions — see separate page on Peripheral Bypass Surgery. BEST-CLI trial (2022) demonstrated that bypass with a suitable great saphenous vein (GSV) conduit was superior to endovascular for CLTI patients with an adequate GSV (Cohort 1): significantly lower rate of major adverse limb events (amputation, revascularisation, vascular death). In patients without adequate GSV (Cohort 2), bypass and endovascular were equivalent.

Effective PAD treatment delivers benefits across three domains: systemic cardiovascular risk reduction, symptomatic improvement in walking ability and quality of life, and limb salvage in CLTI patients.

Cardiovascular risk reduction (medical therapy):

• High-intensity statin therapy reduces MACE (myocardial infarction, stroke, cardiovascular death) by 25-35% in PAD patients over 5 years, with absolute risk reductions of 5-10% in this high-baseline-risk population.
• Ramipril in the HOPE trial reduced MI by 22%, stroke by 33%, and cardiovascular death by 26% in PAD patients — including those who were normotensive at baseline.
• Smoking cessation halves the 5-year cardiovascular mortality in PAD patients and substantially reduces amputation risk.

Symptomatic benefit (claudication):

• Supervised exercise therapy improves maximum walking distance by 50-200% over 12 weeks of structured training. This improvement persists at 12-24 months with continued exercise maintenance.
• Cilostazol improves pain-free walking distance by 40-60% and maximum walking distance by 25-50% vs placebo in 12-week RCTs.
• Aorto-iliac stenting for TASC A-B lesions: immediate symptomatic improvement in 85-95% of patients; 5-year primary patency 75-85%.
• Femoropopliteal stenting: 5-year patency 60-70% with modern nitinol stents; 75-80% with drug-eluting stents in selected series.

CLTI / limb salvage outcomes:

• Successful revascularisation for CLTI achieves limb salvage rates of 80% at 1 year and 70% at 3 years across endovascular and surgical series in the contemporary era.
• BEST-CLI Cohort 1 (bypass with adequate GSV vs endovascular): bypass group had 42% lower rate of primary outcome (major amputation, major reintervention, or death) vs endovascular at 2.7 years median follow-up. However, 30-day surgical morbidity is higher for bypass than endovascular; the benefit applies to patients with adequate life expectancy to realise the durability advantage.
• Wound healing in CLTI: revascularisation restores tissue perfusion, enabling healing of ischaemic ulcers; complete wound healing is achieved in 60-80% of patients with adequate revascularisation and wound care.

Treatment risks for PAD vary markedly by modality — medical therapy carries medication side-effect risk, supervised exercise is very low risk, endovascular procedures carry procedural risks, and open surgical bypass carries the highest perioperative risk profile.

Medical therapy risks:

• Statins: Myalgia (5-10% of patients; true myopathy with CK elevation in <1%); rare but serious rhabdomyolysis (<0.1%); new-onset diabetes mellitus (modest absolute risk increase of 0.1-0.2% per year with high-intensity statins); hepatotoxicity (monitoring of LFTs in first 12 weeks). Benefits substantially outweigh risks in PAD.
• Clopidogrel: Bleeding risk (GI, intracranial); rare thrombotic thrombocytopenic purpura (TTP). Clopidogrel resistance in CYP2C19 poor metabolisers (10-15% of population).
• Cilostazol: Absolute contraindication in heart failure (all NYHA classes — PDE-3 inhibition increases cardiac mortality in CHF). Common: headache (34%), diarrhoea (19%), palpitations (14%). Not to be combined with strong CYP3A4 or CYP2C19 inhibitors.

Supervised exercise therapy: Very safe. Cardiac events during supervised exercise occur in <0.02% of sessions. Musculoskeletal injury risk is present but low in structured programmes. CLEVER trial documented no serious exercise-related adverse events.

Endovascular procedures:

• Access site complications: Haematoma (5-10%), pseudoaneurysm (1-2%), arteriovenous fistula (<1%) at femoral puncture site.
• Contrast nephropathy: Risk 1-5% in general population; 10-25% in diabetics with pre-existing CKD. Pre-hydration and minimisation of contrast volume are preventive measures. Consider CO2 angiography in severe CKD.
• Vessel dissection or perforation: <1% risk; managed with covered stents or surgical repair if needed.
• Distal embolisation: Shower of atheromatous debris distally; 1-3% risk; may cause acute limb ischaemia requiring urgent management.
• In-stent restenosis: 20-40% of SFA stents over 2-3 years; managed with repeat balloon angioplasty, cutting balloon, DCB, or repeat stenting.
• Radiation exposure in complex, prolonged endovascular procedures — significant concern for operators; patients receive threshold dose in longest cases.

Perioperative mortality (endovascular): 30-day mortality for elective endovascular PAD procedures is 0.5-1.5%. For CLTI patients with high cardiovascular comorbidity burden, 30-day mortality may be 2-5% even for endovascular procedures.

PAD is a chronic, progressive disease that requires lifelong follow-up for both cardiovascular risk surveillance and monitoring of limb haemodynamics, whether or not revascularisation has been performed. Post-procedural surveillance is structured by modality.

After non-invasive management (medical therapy + SET):

• Annual review of cardiovascular risk factors: fasting lipids, HbA1c, blood pressure, smoking status.
• ABI measurement annually (or if symptoms worsen) to monitor disease progression.
• Referral to vascular surgery if ABI worsens below 0.5, rest pain develops, or wounds appear — these indicate transition to CLTI.
• Supervised exercise programme compliance monitoring; walking diary review at each visit.

After endovascular revascularisation:

• Clinical review and duplex ultrasound surveillance at 1 month, 3 months, 6 months, and annually thereafter.
• ABI measured at each visit; drop of ≥0.15 from post-procedural baseline indicates haemodynamically significant restenosis requiring further imaging.
• Peak systolic velocity (PSV) ratio on duplex ≥2.0-2.5 at a treated segment indicates ≥50% restenosis; PSV ratio ≥3.5 indicates ≥75% restenosis requiring re-intervention planning.
• For aorto-iliac stenting: duplex surveillance at 6 weeks, 6 months, 1 year, then annually.
• For SFA stenting / DCB angioplasty: more intensive surveillance (3-monthly in year 1) due to higher restenosis rates.

After surgical bypass: Detailed surveillance protocol — see Peripheral Bypass Surgery page. In brief: clinical assessment, duplex Doppler ultrasound graft survey, and ABI at 1, 3, 6, and 12 months then annually for vein grafts. Deteriorating graft velocity or ABI drop prompts urgent angiography and intervention before graft occlusion occurs.

CLTI wound care follow-up: Multidisciplinary wound care team follow-up every 1-2 weeks until wound closure; then monthly for 3 months. Ankle and toe pressures monitored to confirm maintained perfusion during healing. Patients with diabetes require podiatric surveillance indefinitely post-CLTI to prevent recurrence and monitor for new neuropathic or ischaemic lesions.

Foot care education: All PAD patients require education on foot care — daily foot inspection, avoidance of barefoot walking, footwear assessment by orthotist, prompt reporting of any skin breaks, blisters, or discolouration. In diabetics with PAD, this is critical — neuropathy may mask pain, delaying presentation of ischaemic wounds until advanced tissue loss has occurred.

The cost of PAD treatment spans a wide range from low-cost medical management to complex high-cost revascularisation and rehabilitation. Healthcare system context (NHS, Medicare/Medicaid, private insurance, or self-pay) significantly affects patient-facing costs.

Medical management (approximate annual cost, private sector):

• High-intensity statin (atorvastatin 80 mg): USD 10-50/year (generic); brand-name versions can be considerably higher where generics are unavailable.
• Clopidogrel 75 mg: USD 30-120/year (generic); approximately USD 1,400/year (brand Plavix in some markets).
• Ramipril 10 mg: USD 20-60/year (generic).
• Cilostazol (Pletal) 100 mg BD: USD 200-500/year (generic in USA and Europe); approximately USD 2,000/year for brand in markets without generic availability.
• Smoking cessation (varenicline 12-week course): USD 300-600 (significant cost offset by cessation benefit).

Supervised exercise therapy: USD 300-1,500 for a 12-week supervised programme; often reimbursed by Medicare in the USA (ICD-10 diagnosis Z87.39 + I70.xx) since 2017 for symptomatic PAD. A significant cost-effectiveness advantage of SET over endovascular intervention exists — CLEVER trial analysis showed SET had a cost advantage of USD 17,000-25,000 per quality-adjusted life year gained versus stenting at 18-month follow-up.

Diagnostic imaging:

• ABI measurement: USD 100-300 (physician office) — often covered by insurance as a screening tool for at-risk populations.
• Duplex ultrasound peripheral arterial mapping: USD 300-700.
• CT angiography (lower extremity runoff): USD 800-2,500.
• MR angiography: USD 1,000-3,500.
• Digital subtraction angiography (diagnostic only): USD 3,000-8,000.

Endovascular procedures:

• Iliac angioplasty and stenting: USD 12,000-35,000 all-inclusive (procedure room, devices, hospital stay); costs vary enormously by country. In India, comparable iliac stenting is performed for USD 3,000-8,000 in accredited hospitals.
• Femoropopliteal stenting with drug-eluting stent: USD 20,000-45,000 in the USA; USD 5,000-12,000 in India, Thailand, or Hungary.
• Infrapopliteal balloon angioplasty: USD 15,000-30,000.

Surgical bypass: USD 35,000-100,000 in the USA including hospital stay, anaesthesia, and follow-up — see Peripheral Bypass Surgery for detailed breakdown. Medical tourism for complex bypass surgery with graft procedures is available in top vascular centres in India (Medanta, Apollo, Fortis) and Turkey at 20-40% of US costs with outcomes data comparable to Western series.

For patients who are not candidates for conventional endovascular or surgical revascularisation — due to prohibitive operative risk, absence of suitable conduit, or exhausted anatomical options — several alternative and emerging therapies offer palliation and may provide marginal limb salvage benefit.

No-option CLTI strategies:

• Spinal cord stimulation (SCS): Epidural neurostimulation has shown benefit in reducing ischaemic rest pain and improving tissue perfusion in no-option CLTI patients in observational studies and small RCTs. Mechanism involves inhibition of sympathetic vasoconstriction and modulation of pain pathways. Not widely adopted due to limited high-quality RCT evidence and high device cost (USD 20,000-60,000).
• Prostanoids (IV prostacyclin / iloprost): Intravenous iloprost (a stable prostacyclin analogue) is used in no-option CLTI to reduce rest pain and promote wound healing. Evidence supports modest benefit — limb salvage improvement of 10-15% in CLTI patients where revascularisation is impossible. Available in Europe and India; not FDA-approved for PAD in the USA.
• Gene therapy (VEGF, HIF-1alpha): Experimental vascular endothelial growth factor (VEGF) gene therapy delivered intramuscularly to ischaemic limb muscle aims to promote therapeutic angiogenesis. Phase II trials (RAVE, TAMARIS) showed disappointing results; no gene therapy product is currently approved for PAD. Next-generation approaches using HIF-1alpha and combination growth factor delivery are in active investigation.
• Stem cell therapy: Autologous bone marrow mononuclear cell or peripheral blood progenitor cell injections into ischaemic limb muscle. Small trials show improvements in TcPO2, ABI, and ulcer healing. RESTORE-CLI trial (USA) was inconclusive; European and Asian studies show more positive signals. Not yet standard of care.

Major amputation as alternative (primary amputation): For patients with unreconstructible anatomy, severe dementia, non-ambulatory status, or severe contralateral limb disease where revascularisation recovery would be unrealistic, a planned below-knee or above-knee amputation followed by prosthetic rehabilitation may offer better quality of life and reduced morbidity than attempting revascularisation. This decision is made in multidisciplinary palliative and vascular care discussion.

Enhanced external counterpulsation (EECP): Non-invasive, pneumatic compressive cuffs applied to calves and thighs during diastole to augment coronary and peripheral perfusion. Some evidence for claudication improvement, but not standard care for PAD.